TIGIT and neoplasm: Using a xenograft model of human melanoma, it was shown that tumour-specific T cells expressing a hybrid molecule containing the TIGIT extracellular domain fused to the CD28 intracellular domain displayed enhanced production of IFN-γ and TNF-α and improved tumour control [44].